PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.\', \'Central Arkansas Veterans Healthcare System, Little Rock, AR, United States of America.\', \'Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.\', \'Center for Microbial Pathogenesis and Host Inflammatory Responses, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.\', \'Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.\', \'Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.\', \'Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1371/journal.pone.0257016
?:doi
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 34478478
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
is ?:relation_isRelatedTo_publication of
?:title
  • Development of ACE2 autoantibodies after SARS-CoV-2 infection.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all